

Pending Claims After Amendments

34. A composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises:

- a) a light chain variable region, wherein the light chain variable region comprises:
 - i) a CDRL1 amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5;
 - ii) a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:13;
 - iii) a CDRL3 amino acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:19, and SEQ ID NO:21;
 - iv) an FRL1 amino acid sequence consisting of SEQ ID NO:71;
 - v) an FRL2 amino acid sequence consisting of SEQ ID NO:72;
 - vi) an FRL3 amino acid sequence consisting of SEQ ID NO:73; and
 - vii) an FRL4 amino acid sequence consisting of SEQ ID NO:74.
- b) a heavy chain variable region, wherein the heavy chain variable region comprises:
 - i) a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:25;
 - ii) a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, and SEQ ID NO:39;
 - iii) a CDRH3 amino acid sequence selected from the group consisting of SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, and SEQ ID NO:57;
 - iv) an FRH1 amino acid sequence consisting of SEQ ID NO:79;
 - v) an FRH2 amino acid sequence consisting of SEQ ID NO:80;
 - vi) an FRH3 amino acid sequence consisting of SEQ ID NO:81; and
 - vii) an FRH4 amino acid sequence consisting of SEQ ID NO:82.

35. The composition of Claim 34, wherein the CD20 binding molecule comprises the AME 33 Fab.

36. The composition of Claim 34, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 5.0×10^{-10} M or less, and a dissociation rate (k_{off}) for human CD20 of $5.0 \times 10^{-4} \text{ s}^{-1}$ or less.

37. The composition of Claim 36, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 1.5×10^{-10} M or less.

38. The composition of Claim 36, wherein the CD20 binding molecule has a dissociation rate (k_{off}) for human CD20 of $2.5 \times 10^{-4} \text{ s}^{-1}$ or less.

39. The composition of Claim 36, wherein the CD20 binding molecule has an association rate (k_{on}) for human CD20 of $5.0 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ or greater.

40. A method of treating B cell lymphoma comprising administering to a subject a composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises:

- a) a light chain variable region, wherein the light chain variable region comprises:
 - i) a CDRL1 amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5;
 - ii) a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:13;
 - iii) a CDRL3 amino acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:19, and SEQ ID NO:21;
 - iv) an FRL1 amino acid sequence consisting of SEQ ID NO:71;
 - v) an FRL2 amino acid sequence consisting of SEQ ID NO:72;
 - vi) an FRL3 amino acid sequence consisting of SEQ ID NO:73; and
 - vii) an FRL4 amino acid sequence consisting of SEQ ID NO:74.
- b) a heavy chain variable region, wherein the heavy chain variable region comprises:
 - i) a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:25;
 - ii) a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, and SEQ ID NO:39;

- iii) a CDRH3 amino acid sequence selected from the group consisting of SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, and SEQ ID NO:57;
- iv) an FRH1 amino acid sequence consisting of SEQ ID NO:79;
- v) an FRH2 amino acid sequence consisting of SEQ ID NO:80;
- vi) an FRH3 amino acid sequence consisting of SEQ ID NO:81; and
- vii) an FRH4 amino acid sequence consisting of SEQ ID NO:82.

41. The method of Claim 40, wherein the CD20 binding molecule comprises the AME 33 Fab.

42. The method of Claim 40, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 5.0×10^{-10} M or less, and a dissociation rate (k_{off}) for human CD20 of $5.0 \times 10^{-4} \text{ s}^{-1}$ or less.

43. The method of Claim 42, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 1.5×10^{-10} M or less.

44. The method of Claim 42, wherein the CD20 binding molecule has a dissociation rate (k_{off}) for human CD20 of $2.5 \times 10^{-4} \text{ s}^{-1}$ or less.

45. The method of Claim 42, wherein the CD20 binding molecule has an association rate (k_{on}) for human CD20 of $5.0 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ or greater.

46. The method of Claim 40, wherein the B cell lymphoma is Non-Hodgkin's lymphoma.

47. The method of Claim 46, wherein the Non-Hodgkin's lymphoma is Waldenstrom's macroglobulinemia.